Next-Generation CAR-T Cell Therapies for Cancer | Lyell
Lyell Immunopharma is a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. Founded in 2018 and headquartered in South San Francisco, Lyell combines proprietary genetic and epigenetic T-cell reprogramming technologies with an in-house manufacturing facility (LyFE Manufacturing Center) to create potent, durable cell therapies designed to deliver lasting remissions with a single treatment.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2025
Jun 2021
Mar 2020
Mar 2020
Mar 2019
Jan 2018
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
